首页> 外文会议>International conference on lasers and application >DYNAMICS OF ACTIVATION OF CELLULAR IMMUNITY AND INFLAMMATION MARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS, WITH THE USE OF LOW LEVEL INFRA RED PULSE LASER THERAPY (LL-IRPLT).
【24h】

DYNAMICS OF ACTIVATION OF CELLULAR IMMUNITY AND INFLAMMATION MARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS, WITH THE USE OF LOW LEVEL INFRA RED PULSE LASER THERAPY (LL-IRPLT).

机译:黄曲调关节炎患者细胞免疫和炎症标志物激活动力学,利用低水平红外脉冲激光治疗(LL-IRPLT)。

获取原文

摘要

This study is an investigation of the influence of LLP-IR-LT (λ=890 nm), on the activation markers of the immunity system in sera patients with RA. We have studied 137 patients with proved RA forming elementary group and 29 chosen at random representing the control - placebo group. The levels of soluble receptors and neopterin in sera were examined in 53 RA patients from the elementary and in 12 from the control group. These patients were subjected to dynamic determination of soluble TNFα receptors (sTNF- αR), sIL-2R and neopterin by immunoenzym method; and of C-reactive protein (CRP) by radioimmunodiffusion or by immunoenzym method. Due to the LLP-IR-LT therapy, a significant decrease of previously increased level of the sTNF- αR (p<0.01), of neopterin (p<0.05), and of sIL-2R (p<0.05) was registered. Also a significant decrease of previously increased CRP (p<0.01) concentration was registered. Placebo group demonstrates significantly increased level of sTNF-αR-(p<0.01) and CRP-(p<0.01) after LLP-IR-LT. The obtained results represent a pathophysiological basis of LL-IRPLT application in RA, which is connected with the suppression of the functional activity of previously activated macrophages (the main source of the neopterin and sTNFaR), while the suppression of activated T lymphocytes (main source of the sIL-2R).
机译:该研究是对LLP-IR-LT(λ= 890nm)的影响的研究,在血清患者RA患者的免疫系统的激活标志物上的影响。我们研究过137名患有验证的RA患者,形成基本组和29例,随机选择控制 - 安慰剂组。在来自对照组的53名Ra患者中,在53例患者中检查血清中可溶受体和Neopterin的水平。通过免疫酶方法对这些患者进行动态测定可溶性TNFα受体(STNF-αR),SIL-2R和NeOpterin;通过放射免疫幂偏移或通过免疫酶方法进行C反应蛋白(CRP)。由于LLP-IR-LT疗法,注册了Neopterin(P <0.05)的STNF-αr(P <0.01)的STNF-αR(P <0.01)水平的显着降低,并注册了SIL-2R(P <0.05)。还在注册先前增加的CRP(P <0.01)浓度的显着降低。安慰剂组在LLP-IR-LT之后显示出显着增加的STNF-αR-(P <0.01)和CRP-(P <0.01)水平。所得结果代表了在RA中的LL-IRPLT应用的病理生理学基础,其与抑制先前活化的巨噬细胞的功能活性(Neopterin和STNFAR的主要来源),而抑制活性的T淋巴细胞(主要来源SIL-2R)。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号